{"id":"NCT02836236","sponsor":"Gilead Sciences","briefTitle":"Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-19","primaryCompletion":"2017-04-05","completion":"2023-09-18","firstPosted":"2016-07-18","resultsPosted":"2018-04-18","lastUpdate":"2024-10-02"},"enrollment":155,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HBV","Chronic HBV Infection"],"interventions":[{"type":"DRUG","name":"TAF","otherNames":["GS-7340","Vemlidy®"]},{"type":"DRUG","name":"TDF","otherNames":["Viread®"]},{"type":"DRUG","name":"TAF Placebo","otherNames":[]},{"type":"DRUG","name":"TDF Placebo","otherNames":[]}],"arms":[{"label":"Double-Blind TAF","type":"EXPERIMENTAL"},{"label":"Double-Blind TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open-label TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection in China.","primaryOutcome":{"measure":"Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Double-Blind Treatment Phase: TAF 25 mg","deltaMin":89.4,"sd":null},{"arm":"Double-Blind Treatment Phase: TDF 300 mg","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":12},"locations":{"siteCount":29,"countries":["China"]},"refs":{"pmids":["34221918","38779514","37771546"],"seeAlso":["https://www.gileadclinicaltrials.com/study?nctid=NCT02836236"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":104},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Covid-19","Hepatic steatosis","Hyperlipidaemia"]}}